Motley Fool6h agoneutral
Eli Lilly (LLY) Q2 2026 Earnings Call TranscriptRevenue surged 48% on Mounjaro and Zepbound demand, with full-year guidance raised.
Actualités
Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
323last 24h
2136last 7d
376● bullish (7d)
188● bearish (7d)
204publishers
Moby1d agoneutral
Absci Corporation Q2 2026 Earnings Call SummaryMoby summary of Absci Corporation's Q2 2026 earnings call
MarketBeat1d agoneutral
Absci Q2 Earnings Call HighlightsAbsci (NASDAQ:ABSI) outlined progress in its clinical program for ABS-201, a prolactin receptor-targeting antibody being studied for pattern hair loss and planned for development in endometriosis, while reporting a larger cash balance following a June equity offering and strategic investment from El
MarketBeat4d agoneutral
Eli Lilly and Company Q2 Earnings Call HighlightsEli Lilly and Company (NYSE:LLY) reported 48% revenue growth in the second quarter of 2026, driven primarily by continued demand for its cardiometabolic medicines MOUNJARO and ZEPBOUND, while raising its full-year revenue and earnings guidance. Chair and CEO Dave Ricks said the company delivered gr
Benzinga7d agoneutral
How To Earn $500 A Month From Eli Lilly Stock Ahead Of Q2 EarningsEli Lilly and Company will release its second-quarter earnings report before the opening bell on Wednesday, Aug. 5. Analysts expect the company to report quarterly earnings of $6.58 per share, up from $6.31 per share in the year-ago period. The...
Moby7d agoneutral
Eli Lilly and Company Q2 2026 Earnings Call SummaryMoby summary of Eli Lilly and Company's Q2 2026 earnings call
Moby7d agoneutral
Charles River Laboratories International, Inc. Q2 2026 Earnings Call SummaryMoby summary of Charles River Laboratories International, Inc.'s Q2 2026 earnings call
Barrons.com7d agoneutral
Lilly Stock Jumps on Earnings Beat as Mounjaro Revenue Nearly DoublesEli Lilly posted a blockbuster second quarter fueled by continued demand for its portfolio of GLP-1 medications. The world’s biggest drugmaker by market value reported adjusted earnings of $8.38 a share in the period, better than the $6.01 consensus estimate among analysts polled by FactSet. Revenue surged 48% to nearly $23 billion—Wall Street was looking for $20.7 billion.
Investing.com7d agoneutral
Eli Lilly shares pop as weight-loss drug demand fuels guidance hikeInvesting.com -- Eli Lilly shares jumped more than 5% in premarket trading Wednesday after the U.S. pharma giant raised its annual revenue guidance amid strong demand for its popular weight-loss and diabetes drugs.
Barrons.com8d agoneutral
Novo Nordisk Raises Earnings Guidance. The Stock Sinks.The Danish drugmaker continues to rely on the success of semaglutide, branded as Wegovy for weight loss and Ozempic for diabetes.
Zacks8d agoneutral
Pfizer (PFE) Q2 Earnings and Revenues Top EstimatesPfizer (PFE) delivered earnings and revenue surprises of +13.24% and +4.04%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Investopedia8d agoneutral
Here’s How Much Traders See Eli Lilly Stock Moving After EarningsEli Lilly is scheduled to report earnings Wednesday morning, with traders expecting the drugmaker’s stock could potentially approach last month’s highs following the results.
The Wall Street Journal9d agoneutral
SpaceX Earnings, Jobs Numbers: What to Watch This WeekToday Earnings (a.m.): Merck, Pfizer, McDonald's, Caterpillar, Spotify, Apollo, TPG, Marathon Petroleum, Archer-Daniels-Midland, DuPont, Kimberly-Clark Earnings (p.m.): SpaceX, Advanced Micro Devices, ...
MarketBeat9d agoneutral
Inspire Medical Systems Q2 Earnings Call HighlightsInspire Medical Systems (NYSE:INSP) reported second-quarter revenue of $200.6 million, down 7.6% from a year earlier, as coding and reimbursement disruptions continued to affect procedure volumes. The company said results exceeded its internal expectations for profitability and cash flow, prompting
Barchart10d agoneutral
Earnings, PMI and Other Key Things to Watch this WeekMarkets enter an earnings-dominated week with a huge concentration of corporate results spanning technology, industrials, healthcare, consumer discretionary, and entertainment sectors. This will provide a critical assessment of economic health and corporate fundamentals amid persistent uncertainty about technology sector valuations and AI infrastructure spending.
Investor's Business Daily12d agoneutral
AMD Stock Rebounds With Chips Ahead Of Q2 Report; SpaceX Earnings, Lockup Expiration Loom LargeAMD stock keeps its latest pullback contained compared with many other chip stocks as its second-quarter earnings report looms large.
Reuters Videos19d agoneutralVIDEO
Nasdaq lags on angst over AI spending ahead of earnings reports<body><p>STORY: U.S. stocks ended mixed on Friday, with the Dow gaining just under half a percent, the S&P 500 virtually flat and the tech-heavy Nasdaq sliding nearly two-thirds of a percent.</p><p>The S&P 500 technology index underperformed the broader market as chip stocks fell, with Intel dropping nearly 8% despite forecasting quarterly profit and revenue above Wall Street estimates.</p><p>Enthusiasm for the AI trade weakened after Alphabet's announcement earlier this week of a plan to hike capital spending even as it burns cash.</p><p>Richard Reyle, chief investment officer at Questar Capital Partners, said that as a result investors are rotating into what he called "safer parts of the market."</p><p>"Pharmaceuticals have been flying, and that's been, I think, where we see the rotation of the market right now. [FLASH] You look at the iShares, pharmaceutical fund, it's big components that are J&J and Eli Lilly, they're at all-time highs. And they're still relatively not super expensive stocks. So I think that's a place that can be bought and held. And of course, energy. Exxon's going to announce earnings next week. I bet they're going to be a blockbuster and they're going to continue to be because they make money at $60 a barrel. At $100 a barrel, forget about it. They do very well."</p><p>The S&P 500 real estate sector also outperformed during the session. Its leading gainer was Digital Realty Trust, which rallied 11% after it raised its full-year forecast for funds from operations.</p><p>Among other gainers, shares of SLB climbed 11% after the oilfield services firm beat expectations for second-quarter profit.</p><p>Investors now turn their attention to quarterly results next week from Magnificent 7 megacaps Microsoft, Amazon, Meta and Apple.</p></body>
Barchart21d agoneutral
What You Need to Know Ahead of Eli Lilly's Earnings ReleaseEli Lilly will release its second-quarter earnings next month, and analysts anticipate a double-digit bottom-line growth.
StockStory22d agoneutral
Eli Lilly (LLY): Buy, Sell, or Hold Post Q1 Earnings?Eli Lilly has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 6.5% to $1,149 per share while the index has gained 8.4%.
MT Newswires22d agoneutral
Top Midday Stories: 3M Shares Rise on Strong Guidance; Novo Nordisk Sues Eli Lilly Over GLP-1 AdvertisingAll three major US stock indexes were up in late-morning trading Tuesday, as investors focused on so
Investor's Business Daily47d agoneutral
Nike Stock Languishes, But Looming Earnings Report Fuels Turnaround OptimismEarnings are coming up for Nike as the company tries to engineer a turnaround, but Nike stock continues to plumb 52-week lows.
Medical Device Network83d agoneutral
Podcast: Supply chains, obesity drugs, and patents dominate Q1 earnings trendsThe healthcare team covers Q1 results from pharma and medtech companies and provides a wrap-up of the key takeaways.
Moby92d agoneutral
Hims & Hers Health, Inc. Q1 2026 Earnings Call SummaryMoby summary of Hims & Hers Health, Inc.'s Q1 2026 earnings call